Influenza B Market

Market Overview:

The 7 major influenza b markets reached a value of US$ 6.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 42.5 Million by 2034, exhibiting a growth rate (CAGR) of 19% during 2024-2034.

The influenza B market has been comprehensively analyzed in IMARC's new report titled "Influenza B Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Influenza B, also known as flu B, is a respiratory illness caused by the influenza B virus. Some of the common symptoms associated with the ailment include sudden onset of fever, body aches, fatigue, cough, sore throat, nasal congestion, headache, etc. Various gastrointestinal indications, such as nausea, vomiting, diarrhea, etc., may also occur, particularly in children. In many cases, numerous severe symptoms like difficulty breathing, chest pain, confusion, persistent high fever, etc., may develop. The indications of influenza B can vary in severity, but they generally cause significant discomfort and can last for several days to a week or more. Diagnosing the condition involves a combination of clinical evaluation, patient history, and laboratory testing. Healthcare providers may consider the patient's symptoms, medical history, and physical examination findings to determine the possibility of influenza B. Numerous laboratory procedures, such as rapid antigen tests and molecular assays like reverse transcription-polymerase chain reaction (RT-PCR), are commonly used to confirm the presence of the influenza B virus. These tests analyze several respiratory samples, including nasal and throat swabs, to detect viral genetic material or specific viral proteins.

The escalating incidence of viral infections during the colder months, which affect the respiratory epithelial cells, is primarily driving the influenza B market. Furthermore, the increasing prevalence of weakened immunity that can impair the respiratory tract's natural defense mechanisms, making individuals more susceptible to viral infections, is also creating a positive outlook for the market. Apart from this, the widespread adoption of neuraminidase inhibitors, such as oseltamivir, zanamivir, peramivir, etc., since they inhibit the release of newly formed viral particles, thus slowing down viral replication, is acting as another significant growth-inducing factor. Moreover, numerous key players are making extensive investments in R&D activities to introduce host-directed therapies that modulate the host's immune response to influenza infection, aiming to reduce inflammation, improve immune defense, and minimize tissue damage. This, in turn, is also further bolstering the market growth. Additionally, the ongoing advancements in drug delivery systems, such as the launch of intranasal sprays, inhalers, and long-acting formulations, which offer potential benefits in terms of ease of administration, enhanced drug absorption, and prolonged therapeutic effect, are expected to drive the influenza B market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the influenza B market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for influenza B and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the influenza B market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the influenza B market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the influenza B market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current influenza B marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the influenza B market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the influenza B market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the influenza B market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of influenza B across the seven major markets?
• What is the number of prevalent cases (2018-2034) of influenza B by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of influenza B by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with influenza B across the seven major markets?
• What is the size of the influenza B patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of influenza B?
• What will be the growth rate of patients across the seven major markets?
   

Influenza B: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for influenza B drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the influenza B market?
• What are the key regulatory events related to the influenza B market?
• What is the structure of clinical trial landscape by status related to the influenza B market?
• What is the structure of clinical trial landscape by phase related to the influenza B market?
• What is the structure of clinical trial landscape by route of administration related to the influenza B market?